Status:
COMPLETED
AZD2066 Cocktail Study
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Pain
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
The aims of this study are to examine the effect of repeated doses of AZD2066 and of caffeine, bupropion, tolbutamide, omeprazole, metoprolol and midazolam on the blood concentrations of each other
Eligibility Criteria
Inclusion
- Provision of informed consent prior to any study-specific procedures
- Healthy volunteers with BMI between 18 and 30 kg/m2
- Medical and surgical history and physical examination without any clinically significant findings
- Non smokers or past smokers who have stopped smoking within the last 6 months.
Exclusion
- History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, personality disorder or other significant psychiatric disorders or any other major disorder that may interfere with the objectives of the study, as judged by the Investigator
- Clinically significant illness as judged by the Investigator, within four weeks before the first administration of investigational product.
- Female subjects who have a positive pregnancy test or who are pregnant or breast-feeding
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00930306
Start Date
June 1 2009
End Date
September 1 2009
Last Update
October 27 2009
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
London, United Kingdom
2
Research Site
Manchester, United Kingdom